An experimental gene-editing treatment shows promise for permanently lowering levels of cholesterol and triglycerides, ...

Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025--Phase 1 ...

CRISPR Therapeutics (CRSP) posts new data from an early stage trial for CTX310, an in vivo gene editing therapy for heart ...

A single infusion of CRISPR Therapeutics' experimental gene therapy was safe and reduced levels of harmful LDL cholesterol and triglycerides by half in four people taking the highest dose, raising ...

A CRISPR-based gene editing therapy dramatically reduced levels of LDL cholesterol and triglycerides in patients with heart ...

The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical ...

The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred. Intellia is working with experts to create a risk management program for nex ...

The Cambridge-based biotech company is studying the use of Crispr, the Nobel Prize-winning gene-editing technology, to treat ...

In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and ...

A patient with transthyretin amyloidosis (ATTR) who received the investigational gene therapy nexiguran ziclumeran (nex-z) in ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $55.16, demonstrating a -2.56% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily ...

The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...